Peter Kaiser, who serves as Chief Development Officer at Ocular Therapeutix, Inc. (NASDAQ: OCUL), reported the sale of 2,810 shares of the company’s common stock on February 23, 2026, according to a Form 4 filing with the Securities and Exchange Commission.
The disposition was executed at a weighted average price of $8.28 per share, yielding $23,266 in proceeds. Transaction prices recorded on the filing ranged between $8.23 and $8.36 per share. After completing the sale, Kaiser directly holds 269,108 shares of Ocular Therapeutix.
The filing states the shares were sold specifically to meet tax withholding obligations associated with the vesting of restricted stock units.
Market context and current valuation
Following the reported sale, the company’s share price has experienced notable near-term movement. Over the past week the stock advanced roughly 38% and is trading at $9.50, with a stated market capitalization of $2.06 billion.
According to InvestingPro analysis referenced in the filing, Ocular Therapeutix shows a balance sheet position with more cash than debt, though it carries a "WEAK" financial health score. Analyst price targets cited range from $18 to $34. The filing also notes that comprehensive Pro Research Reports covering OCUL and more than 1,400 other U.S. equities are available on InvestingPro for investors seeking deeper analysis.
Clinical development update and market reaction
In separate company disclosures, Ocular Therapeutix announced positive Phase 3 data for its investigational wet age-related macular degeneration (AMD) therapy AXPAXLI. The SOL-1 trial results reported that 74.1% of patients receiving AXPAXLI maintained their vision at Week 36 versus 55.8% of patients treated with aflibercept, a statistically significant difference cited by the company. Despite that outcome, the company’s shares fell 27% following the announcement.
Analyst responses to the SOL-1 data have varied. Needham lowered its price target for Ocular Therapeutix from $20 to $18 but kept a Buy rating, citing a narrower-than-expected efficacy gap as the rationale. Raymond James retained a Strong Buy rating and a $28 price target, highlighting the FDA’s policy shift toward accepting a single pivotal study for approval as advantageous for Ocular’s NDA submission. RBC Capital reiterated an Outperform rating with a $30 price target, stating there have been no fundamental changes to the company’s outlook despite the share price decline.
Bottom line
The insider sale by Kaiser was executed for tax purposes tied to RSU vesting and occurred amid significant share-price movement and active analyst debate over recent clinical data. The combination of corporate cash position, a weak financial health score, divergent analyst targets and volatility after the SOL-1 results underscores continuing investor scrutiny of Ocular Therapeutix.